Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.
Journal: Journal of medicinal chemistry 20111208
Title: Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells.
Journal: Journal of leukocyte biology 20051001
Title: Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.
Journal: JAMA 20050511
Title: Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
Journal: European journal of pharmacology 20040319
Title: Interactions among three classes of mediators explain antigen-induced bronchoconstriction in the isolated perfused and ventilated guinea pig lung.
Journal: The Journal of pharmacology and experimental therapeutics 20031001
Title: Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis.
Journal: FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030901
Title: Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin.
Journal: British journal of pharmacology 20030801
Title: Inhibition of 5-lipoxygenase activating protein decreases proteinuria in diabetic rats.
Journal: Journal of nephrology 20030101
Title: A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD.
Journal: Chest 20020701
Title: Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition.
Journal: Arthritis and rheumatism 20020701
Title: Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines.
Journal: The Journal of rheumatology 20020301
Title: Inhibition of 5-LO activating protein (FLAP) activity decreases proteinuria in streptozotocin (STZ)-induced diabetic rats.
Journal: Advances in experimental medicine and biology 20020101
Title: MUC5AC mucin release from human airways in vitro: effects of indomethacin and Bay X1005.
Journal: Mediators of inflammation 20010201
Title: Leukotriene C4 is a tight-binding inhibitor of microsomal glutathione transferase-1. Effects of leukotriene pathway modifiers.
Journal: The Journal of biological chemistry 19990122
Title: Pharmacological modulation of human platelet leukotriene C4-synthase.
Journal: Biochemical pharmacology 19970321
Title: Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds.
Journal: Biochemical pharmacology 19930107
Title: Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis.
Journal: Nature 19900118
Title: Hatzelmann A, et al. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase. Agents Actions. 1994 Nov;43(1-2):64-8.
Title: Müller-Peddinghaus R, et al. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J Pharmacol Exp Ther. 1993 Oct;267(1):51-7.
Title: Fruchtmann R, et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions. 1993 Mar;38(3-4):188-95.
Title: Jawień J, et al. BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
